Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy?

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 3, 2010, Pages

  Rizzo, Sergio ^a   Bronte, Giuseppe ^a   Fanale, Daniele ^a   Corsini, Lidia ^a   Silvestris, Nicola ^b   Santini, Daniele ^c   Gulotta, Gaspare ^d   Bazan, Viviana ^a   Gebbia, Nicola ^a   Fulfaro, Fabio ^a   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Driver mutations; EGFR; KRAS; Monoclonal antibodies

Indexed keywords

AMPHIREGULIN; B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAF INHIBITOR; RAS INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; GENE MUTATION; HUMAN; METASTASIS; MISSENSE MUTATION; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 78649744892     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70021-9     Document Type: Article

References (54)

1. Parkin DM, Bray F, Ferlay J, Pisani P Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Carpenter SG, Carson J, Fong Y Regional liver therapy using oncolytic virus to target hepatic colorectal metastases. Semin Oncol 2010, 37:160-169.
3. Russo A, Rizzo S, Bronte G, et al. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology 2009, 77(Suppl 1):57-68.
4. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319:525-532.
5. Weinstein IB, Joe A Oncogene addiction. Cancer Res 2008, 68:3077-3080. discussion 80.
6. Amador ML, Hidalgo M Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer. Clin Colorectal Cancer 2004, 4:51-62.
7. Tedesco KL, Lockhart AC, Berlin JD The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. Curr Treat Options Oncol 2004, 5:393-403.
8. Harari PM Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004, 11:689-708.
9. Harding J, Burtness B Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barc) 2005, 41:107-127.
10. Lurje G, Lenz HJ EGFR signaling and drug discovery. Oncology 2009, 77:400-410.
11. Vokes EE, Chu E Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 2006, 20:15-25.
12. Spindler KL, Lindebjerg J, Nielsen JN, et al. Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods. Int J Oncol 2006, 29:1159-1165.
13. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005, 23:1803-1810.
14. Moroni M, Sartore-Bianchi A, Benvenuti S, Artale S, Bardelli A, Siena S Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. Ann Oncol 2005, 16:1848-1849.
15. Ooi A, Takehana T, Li X, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004, 17:895-904.
16. Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009, 27:5068-5074.
17. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25:3230-3237.
18. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009, 69:1851-1857.
19. Schubbert S, Shannon K, Bollag G Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7:295-308.
20. Bos JL ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689.
21. Yarden Y, Sliwkowski MX Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
22. Siena S, Sartore-Bianchi A, Di Nicolantonio F, alfour J, Bardelli A Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009, 101:1308-1324.
23. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001, 85:692-696.
24. Boughdady IS, Kinsella AR, Haboubi NY, Schofield PF K-ras gene mutation in colorectal adenomas and carcinomas from familial adenomatous polyposis patients. Surg Oncol 1992, 1:269-274.
25. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007, 67:2643-2648.
26. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
27. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
28. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
29. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
30. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671.
31. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27:672-680.
32. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563-572.
33. Maughan TS, Adams R, Smith CG, et al. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial. J Clin Oncol 2010, 28:15s. abstr 3502.
34. Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002, 13:1438-1446.
35. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010, 28:466-474.
36. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
37. Bokemeyer C, Kohne C, Rougier P, Stroh C, Schlichting M, Van Cutsem E Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. J Clin Oncol 2010, 28:15s. abstr 3506.
38. Tol J, Nagtegaal ID, Punt CJ BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009, 361:98-99.
39. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wildtype metastatic colorectal cancer. Br J Cancer 2009, 101:715-721.
40. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009, 101:465-472.
41. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
42. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005, 353:2012-2024.
43. Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008, 122:2255-2259.
44. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
45. Goel A, Arnold CN, Niedzwiecki D, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004, 64:3014-3021.
46. Guanti G, Resta N, Simone C, et al. Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis. Hum Mol Genet 2000, 9:283-287.
47. Shin KH, Park YJ, Park JG PTEN gene mutations in colorectal cancers displaying microsatellite instability. Cancer Lett 2001, 174:189-194.
48. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007, 97:1139-1145.
49. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 27:5924-5930.
50. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009, 27:2622-2629.
51. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4:e7287.
52. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
53. Jhawer M, Goel S, Wilson AJ, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008, 68:1953-1961.
54. Razis E, Briasoulis E, Vrettou E, et al. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer 2008, 8:234.